Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Adma Biologics (ADMA) Consolidated Net Income: 2011-2025

Historic Consolidated Net Income for Adma Biologics (ADMA) over the last 12 years, with Sep 2025 value amounting to $36.4 million.

  • Adma Biologics' Consolidated Net Income rose 1.45% to $36.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $209.4 million, marking a year-over-year increase of 207.41%. This contributed to the annual value of $197.7 million for FY2024, which is 800.00% up from last year.
  • As of Q3 2025, Adma Biologics' Consolidated Net Income stood at $36.4 million, which was up 6.46% from $34.2 million recorded in Q2 2025.
  • In the past 5 years, Adma Biologics' Consolidated Net Income ranged from a high of $111.9 million in Q4 2024 and a low of -$18.8 million during Q2 2021.
  • For the 3-year period, Adma Biologics' Consolidated Net Income averaged around $24.3 million, with its median value being $26.9 million (2025).
  • As far as peak fluctuations go, Adma Biologics' Consolidated Net Income tumbled by 49.63% in 2023, and later skyrocketed by 1,299.96% in 2024.
  • Adma Biologics' Consolidated Net Income (Quarterly) stood at -$16.5 million in 2021, then grew by 28.55% to -$11.8 million in 2022, then slumped by 49.63% to -$17.6 million in 2023, then skyrocketed by 734.15% to $111.9 million in 2024, then climbed by 1.45% to $36.4 million in 2025.
  • Its Consolidated Net Income stands at $36.4 million for Q3 2025, versus $34.2 million for Q2 2025 and $26.9 million for Q1 2025.